NCT00310180 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 1619
- group Id
- BG001
- value
- 3399
- group Id
- BG002
- value
- 3312
- group Id
- BG003
- value
- 1389
- group Id
- BG004
- value
- 9719
- units
- Participants
- groups
- description
- Group 1 (Oncotype DX recurrence score =\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO
- id
- BG000
- title
- Arm A
- description
- Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO
- id
- BG001
- title
- Arm B
- description
- Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO Combination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials
- id
- BG002
- title
- Arm C
- description
- Group 3 (Oncotype DX recurrence score \>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO Combination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials
- id
- BG003
- title
- Arm D
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 58
- group Id
- BG001
- value
- 154
- group Id
- BG002
- value
- 157
- group Id
- BG003
- value
- 79
- group Id
- BG004
- value
- 448
- title
- <=40 years
- measurements
- group Id
- BG000
- value
- 371
- group Id
- BG001
- value
- 985
- group Id
- BG002
- value
- 920
- group Id
- BG003
- value
- 330
- group Id
- BG004
- value
- 2606
- title
- 41-50 years
- measurements
- group Id
- BG000
- value
- 563
- group Id
- BG001
- value
- 1235
- group Id
- BG002
- value
- 1206
- group Id
- BG003
- value
- 512
- group Id
- BG004
- value
- 3516
- title
- 51-60 years
- measurements
- group Id
- BG000
- value
- 518
- group Id
- BG001
- value
- 868
- group Id
- BG002
- value
- 895
- group Id
- BG003
- value
- 395
- group Id
- BG004
- value
- 2676
- title
- 61-70 years
- measurements
- group Id
- BG000
- value
- 109
- group Id
- BG001
- value
- 157
- group Id
- BG002
- value
- 134
- group Id
- BG003
- value
- 73
- group Id
- BG004
- value
- 473
- title
- 71-75 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1619
- group Id
- BG001
- value
- 3399
- group Id
- BG002
- value
- 3312
- group Id
- BG003
- value
- 1389
- group Id
- BG004
- value
- 9719
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 39
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 82
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 132
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 405
- title
- Asian
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 30
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 107
- group Id
- BG001
- value
- 236
- group Id
- BG002
- value
- 235
- group Id
- BG003
- value
- 115
- group Id
- BG004
- value
- 693
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 1361
- group Id
- BG001
- value
- 2883
- group Id
- BG002
- value
- 2783
- group Id
- BG003
- value
- 1162
- group Id
- BG004
- value
- 8189
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 10
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 51
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 130
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 353
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 432
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 432
- title
- 0-5
- measurements
- group Id
- BG000
- value
- 1187
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1187
- title
- 6-10
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1214
- group Id
- BG002
- value
- 1159
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2373
- title
- 11-15
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1368
- group Id
- BG002
- value
- 1344
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2712
- title
- 16-20
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 817
- group Id
- BG002
- value
- 809
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1626
- title
- 21-25
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 598
- group Id
- BG004
- value
- 598
- title
- 26-30
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 315
- group Id
- BG004
- value
- 315
- title
- 31-35
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 158
- group Id
- BG004
- value
- 158
- title
- 36-40
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 202
- group Id
- BG004
- value
- 202
- title
- 41-50
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 116
- title
- >50
- description
- The Oncotype DX assay is a 21-gene assay that predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer. Oncotype DX test results assign a Recurrence Score, and the Oncotype DX Recurrence Score is a continuous score, ranged between 0 and 100, that provides an individual estimate of the 10 year risk of distant recurrence and predicts the likelihood of benefit from chemotherapy. Higher score indicate higher risk of recurrence.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Recurrence score
- unit Of Measure
- Participants
- population Description
- All eligible patients who had on-study data and follow-up data were included in the analysis
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 1619
- group Id
- BG001
- value
- 3399
- group Id
- BG002
- value
- 3312
- group Id
- BG003
- value
- 1389
- group Id
- BG004
- value
- 9719
- units
- Participants
- groups
- description
- Group 1 (Oncotype DX recurrence score =\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO
- id
- BG000
- title
- Arm A
- description
- Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO
- id
- BG001
- title
- Arm B
- description
- Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO Combination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials
- id
- BG002
- title
- Arm C
- description
- Group 3 (Oncotype DX recurrence score \>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment. Anastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO Combination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials
- id
- BG003
- title
- Arm D
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 58
- group Id
- BG001
- value
- 154
- group Id
- BG002
- value
- 157
- group Id
- BG003
- value
- 79
- group Id
- BG004
- value
- 448
- title
- <=40 years
- measurements
- group Id
- BG000
- value
- 371
- group Id
- BG001
- value
- 985
- group Id
- BG002
- value
- 920
- group Id
- BG003
- value
- 330
- group Id
- BG004
- value
- 2606
- title
- 41-50 years
- measurements
- group Id
- BG000
- value
- 563
- group Id
- BG001
- value
- 1235
- group Id
- BG002
- value
- 1206
- group Id
- BG003
- value
- 512
- group Id
- BG004
- value
- 3516
- title
- 51-60 years
- measurements
- group Id
- BG000
- value
- 518
- group Id
- BG001
- value
- 868
- group Id
- BG002
- value
- 895
- group Id
- BG003
- value
- 395
- group Id
- BG004
- value
- 2676
- title
- 61-70 years
- measurements
- group Id
- BG000
- value
- 109
- group Id
- BG001
- value
- 157
- group Id
- BG002
- value
- 134
- group Id
- BG003
- value
- 73
- group Id
- BG004
- value
- 473
- title
- 71-75 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1619
- group Id
- BG001
- value
- 3399
- group Id
- BG002
- value
- 3312
- group Id
- BG003
- value
- 1389
- group Id
- BG004
- value
- 9719
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 39
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 82
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 132
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 405
- title
- Asian
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 30
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 107
- group Id
- BG001
- value
- 236
- group Id
- BG002
- value
- 235
- group Id
- BG003
- value
- 115
- group Id
- BG004
- value
- 693
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 1361
- group Id
- BG001
- value
- 2883
- group Id
- BG002
- value
- 2783
- group Id
- BG003
- value
- 1162
- group Id
- BG004
- value
- 8189
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 10
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 51
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 130
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 353
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 432
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 432
- title
- 0-5
- measurements
- group Id
- BG000
- value
- 1187
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1187
- title
- 6-10
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1214
- group Id
- BG002
- value
- 1159
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2373
- title
- 11-15
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1368
- group Id
- BG002
- value
- 1344
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2712
- title
- 16-20
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 817
- group Id
- BG002
- value
- 809
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1626
- title
- 21-25
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 598
- group Id
- BG004
- value
- 598
- title
- 26-30
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 315
- group Id
- BG004
- value
- 315
- title
- 31-35
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 158
- group Id
- BG004
- value
- 158
- title
- 36-40
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 202
- group Id
- BG004
- value
- 202
- title
- 41-50
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 116
- title
- >50
- description
- The Oncotype DX assay is a 21-gene assay that predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer. Oncotype DX test results assign a Recurrence Score, and the Oncotype DX Recurrence Score is a continuous score, ranged between 0 and 100, that provides an individual estimate of the 10 year risk of distant recurrence and predicts the likelihood of benefit from chemotherapy. Higher score indicate higher risk of recurrence.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Recurrence score
- unit Of Measure
- Participants
- population Description
- All eligible patients who had on-study data and follow-up data were included in the analysis
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle